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Background: Colorectal cancer is one of the most commonly diagnosed cancers and cancer- related death worldwide. Identification of 
new specific biomarkers could be helpful to detection of this malignancy. Altered plasma microRNA expression has been identified in 
many cancers, including colorectal cancer
Objectives: 
.
The main objective of this study was to identify the circulating microRNAs with the most expression changes in colorectal 
cancer patients compared with neoplasm free healthy individuals.
Materials and Methods: MicroRNA expression profiling was performed on plasma samples of 37 colorectal cancer patients and 8 normal 
subjects using microRNA microarray. Quantitative real-time reverse transcription polymerase chain reaction was used to validate the two 
selected altered microR NAs. Plasma samples from 61 colorectal cancer patients and 24 normal subjects were used in our validati
Results: 
on study.
In profiling study we found a panel of six plasma microRNAs with significant downregulation. MicroRNA-142-3p and microRNA-
26a-5p were selected and validated by polymerase chain reaction. Our results demonstrated that expression levels of plasma microRNA-
142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group
Conclusions: 
.
Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel 
noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.
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1. Background
Colorectal carcinoma (CRC) is the third most malignant 
tumor in the world (1) with approximately 10 percent of 
all cancers incidence and mortality (2). It has been shown 
that CRC will be a preventable malignancy when precan-
cerous lesions are diagnosed early. Despite considerable 
progress that has been made over the past two decades 
in CRC diagnostic procedures and therapeutic strategies 
(3-5), however still many of the CRC patients, especially 
those who are diagnosed in advanced stages; do not suit-
ably respond to treatment. Thus intensive researches 
should be done to improve our understanding of biol-
ogy, genetics and epigenetic alterations in CRC for iden-
tifying diagnostic, prognostic and predictive biomarkers 
and finally more effective therapeutic procedures. Recent 
studies have shown that expression of small RNA mole-
cules named microRNA is significantly associated with 
formation and progression of CRC (6-8). MicroRNAs (miR-
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NAs) are a class of small, non-coding, single-stranded, en-
dogenous and highly conserved RNA molecules which 
post-transcriptionally modulate the expression of their 
target genes (9). MiRNAs can influence on colorectal car-
cinogenesis by direct regulation of their target mRNAs as 
oncogenes or tumor suppressor genes. A significant ad-
vantage of miRNAs as useful molecular tools comes from 
the fact that a single miRNA can modulate the expression 
of several mRNAs. So, for identifying the markers with 
greater specificities and sensitivities, working on miRNA 
is preferred (10). Another advantage of using the miRNA 
is their high stability in different physical situations and 
resistance to storage and handling in different biological 
samples (11, 12). Previous studies demonstrated that miR-
NAs are highly stable in serum or plasma samples with 
appropriate concentration (13-15). Valadi et al. in 2007 
reported the secretion of miRNAs in circulation system 
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through exosomal compartments (16). The tumor-specif-
ic expression profile of miRNAs in the body fluids as well 
as tumor tissues is a suitable biomarker for a variety of 
cancers (17-19). Moreover body fluids provide constant, 
non-invasive source of miRNAs as cancer biomarkers.
2. Objectives
In the present study we have compared the miRNAs ex-
pression profiles in plasma of CRC patients and healthy 
individuals hoping to find the miRNAs with significant 
altered expression in the patient group compared to the 
control group.
3. Materials and Methods
3.1. Subjects and Blood Samples
In this study, pre-operative plasma from 61 recently di-
agnosed colorectal cancer patients (including 13 stage I, 
41 stage II and 7 stage III patients) and 24 (age and gender-
matched) healthy subjects as the control were collected 
between 2012 and 2013 at Digestive Disease Research In-
stitute (DDRI), Shariati Hospital, Tehran, Iran (Table 1). Tu-
mors were staged according to the tumor–node–metastasis 
(TNM) staging system guidelines. No significant differenc-
es were observed between the CRC patients and controls in 
the distribution of gender (P value = 0.512, chi-square test) 
and age (P value = 0.8, Independent Samples t test). Normal 
subjects were asymptomatic individuals recruited from a 
colonoscopy screening. The CRC patients group consisted 
of 27 women and 34 men with a median age of 66 years 
(range, 45 - 80) and the healthy subjects consisted of 10 
women and 14 men with a median age of 63 years (range, 
47 - 77). The patients with a history of familial adenoma-
tous polyposis or hereditary non-polyposis CRC or previ-
ous history of malignant tumors were excluded from this 
study. An amount of 5 to 10 milliliters of whole blood were 
obtained from each participant. The plasma was obtained 
by centrifugation at 1200 gr for 10 minutes at 4°C. The su-
pernatant plasma was quickly frozen in -70°C until analy-
sis. Informed consents were obtained from all participants 
for the use of their blood samples in this study. This study 
was approved by the Clinical Research Ethics Committee of 
Shariati Hospital, Tehran University of Medical Sciences.
3.2. RNA Isolation
Total RNA, including miRNA, was extracted from plas-
ma samples by using the miRNA easy Serum/Plasma Kit 
(Qiagen) following the manufacturer’s instruction. For 
normalization of sample-to-sample variation during RNA 
isolation and as internal control, a synthetic miRNA (cel-
miR-39 from C. elegans) was added into each denatured 
sample in equal amounts. RNA concentration and integri-
ty were quantified using NanoDrop-1000 Spectrophotom-
eter (Thermo Fisher Scientific Inc., Wilmington, DE) and 
Agilent’s Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Table 1. Patient Characteristics for Plasma miRNA Analysis
CRC Patients Healthy Subjects
Age,y 64.13 ± 8.673 61.96 ± 8.67
Gender
Male 34 14
Female 27 10
TNM stage
I 13 -
II 41 -
III 7 -
Tumor location
Colon 52 -
Rectum 9 -
3.3. MiRNA Microarray Expression Profiling and Data Analysis
The miRNA expression profiles were generated by us-
ing the Agilent's miRNA Microarray system (V19), (Agi-
lent Technologies, Santa Clara, CA), on plasma samples 
from 37 CRCs (including 9 stage I, 25 stage II and 3 stage 
III patients) and 8 normal controls. This array detects 
2006 human mature miRNAs. Briefly, in labeling step 
100 ng of the diluted total RNA was dephosphorylate by 
calf intestinal alkaline phosphatase followed by dena-
turation with 2.8 µL of 100% DMSO and ligation to Cy-
anine3-pCp using T4 RNA Ligase. After drying the sam-
ples using a vacuum concentrator and treatment with 
GE blocking agent and Hi-RPM hybridization buffer, 
samples were loaded on Agilent SureHyb chamber. In 
hybridization step, samples were hybridized overnight 
to miRNA bead chip in a hybridization oven at 55°C. Af-
ter washing the samples were scanned by Agilent's Mi-
croarray Scanner. Microarray data processing was gen-
erated in the agilent feature extraction software and 
used for further analysis with GeneSpring GX Analysis 
software (Agilent Technologies Inc., USA).
3.4. Quantification of MiRNAs by qRT-PCR
100 ng of extracted total RNA was reverse transcribed 
with a miScript Reverse Transcription Kit (Qiagen, Valen-
cia, CA), in a 20 µL reaction volume according to the man-
ufacture's protocol. MiRNA expression levels were quan-
tified in duplicate by Real-time PCR using SYBR Green 
miScript real-time PCR system (Qiagen, Valencia, CA) 
according to the manufacturer's instructions on Light-
Cycler v.3.5 system (Roche Applied Science, Mannheim, 
Germany). Product amplification was performed using 
miRNA-specific primers and universal primers (Qiagen, 
Valencia, CA). In brief, the 20 µL PCR reaction mixture in-
cluded 2 µL of RT product (10 ng), 10 µL 2x QuantiTect SYBR 
Green PCR Master Mix, PCR primer and universal primer 
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each one 2 µL and 4 µL nuclease free water, was incubated 
at 95°C for 15 minutes., followed by 50 cycles of 94°C for 15 
seconds, 55°C for 20 seconds and 72°C for 20 seconds. The 
expression levels of each miRNA were normalized against 
miR-16 expression and the threshold cycle (Ct) values of 
40 or greater were defined as undetectable. The relative 
expression of plasma miRNA levels between two groups 
was calculated using the 2-∆∆Ct method. GraphPad Prism 
6 was used for data analysis and preparing the graphs.
4. Results
4.1. MicroRNA Expression Profiling
The extracted total RNA concentration ranges were 
from 21.1 to 54.87 ng/µL in plasma samples of CRC patients 
and normal group. By data analysis of miRNA microarray 
on 37 CRC patients and 8 normal subjects, using precise 
significance criteria of a two-fold or greater difference 
in expression level and P value < 0.05, in GeneSpring GX 
software, we found that six miRNAs (miR-142-3p, miR-26a-
5p, miR-27a-3p, miR-326, miR-331-3p and miR-6073) were 
significantly downregulated in CRC patients compared 
to the healthy subjects. The list of these differentially ex-
pressed miRNAs is provided in Table 2.
4.2. Validation Study by qRT-PCR
Among the six differentially expressed miRNAs in our 
profiling study, miR-142-3p and miR-26a-5p were cho-
sen for further qRT-PCR validation study, because they 
showed the most changes in expression level in miRNA 
microarray step. In addition, their misexpressions have 
been shown in different types of cancers. The expres-
sion levels of miR-142-3p and miR-26a-5p were evalu-
ated in the plasma from 61 CRC patients and 24 healthy 
subjects (including the samples used for miRNA micro-
array analysis).
Real-time data analysis showed significant downregula-
tion of miR-142-3p and miR-26a-5p in CRC patients com-
pared to the normal subjects (P value = 0.002 and 0.013 
respectively) (Figure 1 A and B).
In order to evaluate the diagnostic value of the miR-142-
3p and mir-26a-5p in CRC patients, ROC curve analysis 
was performed. These data revealed that miR-142-3p can 
potentially be used as a diagnostic biomarker for distin-
guishing between CRC patients and normal individuals. 
The area under the curve (AUC value) for miR-142-3p was 
71% with the standard error of 0.059 (P value = 0.002) 
while the AUC value for miR-26a-5p was 67% with the stan-
dard error of 0.06 (P value = 0.014) (Figure 2).
Table 2. The Most Differentially Expressed MiRNAs in CRC Patients Versus Normal Subjects
miR Name MiRNAs With Low Expression in Plasma of CRC Patients
P Value Fold Change
miR-142-3p 0.029 11.31
miR-26a-5p 0.023 10.97
miR-27a-3p 0.046 9.58
miR-326 0.038 5.02
miR-331-3p 0.033 9.29
miR-6073 0.048 10.17
P = 0.002
P = 0.013
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Figure 1. Differential Expression of Circulating microrna-142-3p and MicroRNA-26a-5p in a Group of Colorectal Cancer Patients Compared to the Normal 
Individuals (Mann-Whitney Test)
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Figure 2. Area Under Curve of Receiver Operating Characteristic for Microrna-142-3p and Microrna-26a-5p
5. Discussion
Previous studies have shown that compared to the 
mRNA levels, miRNA analysis may be more efficient in 
understanding the biology of the disease (20, 21). The 
main objective of this study was to identify altered ex-
pression circulating miRNAs in patients with colorectal 
carcinoma compared to healthy participants. Circulat-
ing miRNAs are reflective of alterations in tissue ex-
pression of miRNAs and are emerging as biomarkers in 
many malignancies, including colorectal cancer.
In the present study, to identify differentially ex-
pressed circulating miRNAs we have firstly compared 
the expression profile of miRNAs in the plasma samples 
from CRC patients compared to healthy controls using 
a miRNA microarray method and six miRNAs (miR-142-
3p, miR-26a-5p, miR-27a-3p, miR-326, miR-331-3p and 
miR-6073) were found significantly downregulated in 
CRC patients. In order to validate our data, expression 
levels of miR-142-3p and miR-26a were evaluated in a 
subsequent validation study using qRT-PCR method 
and the results showed that the plasma levels of these 
two selected miRNAs were significantly decreased in 
CRC patients compared to the normal group.
Another downregulated miRNA, miR-326 has been al-
ready found to be downregulated in advanced breast 
cancer (22) and also in glioblastoma (23). Furthermore 
miR-326 has been identified as a potential marker as-
sociated with osseous metastasis in a lung cancer 
(24). MiR-331-3p expression has demonstrated to be de-
creased in some malignancy including breast, prostate, 
and pancreas cancer via targeting of human epidermal 
growth factor receptor 2 (HER2) (25, 26) and in glioblas-
toma through targeting the neuropilin-2 (NRP-2) (27). 
Overexpression of the long non-coding RNA HOTAIR 
(Hox transcript antisense intergenic RNA) has been 
identified in a range of tumors, including those of the 
colorectal cancer, hepatocellular carcinoma, pancreatic 
and gastric cancer, and have been shown that miR-331-
3p can directly bind to HOTAIR (28). In a recent study by 
Wei Shen et al. miR-142-3p was found to be downregu-
lated in colon cancer (29). They reported that reduced 
levels of miR-142-3p as a tumor suppressor is associated 
with upregulation of CD133, ATP binding cassette G2 
(ABCG2), and leucine-rich-repeat-containing G-protein-
coupled receptor 5 (Lgr5) by binding to their 3’-UTRs 
and coding sequences. Upregulation of these genes are 
associated with poor prognosis in colon cancer. In addi-
tion Zhou et al. found that miR-142-3p may be involved 
in the regulation of cell proliferation in colorectal can-
cer through targeting the transcription factor 7 (TCF7) 
(30). Another previous study revealed that miR-142-3p 
could regulate FASN expression which is involved in 
cancer cells proliferation and metastasis in CRC (31). 
Previously has been reported that miR-26a could func-
tions as a potential tumor-suppressor by targeting the 
MYC oncogene (32, 33). Furthermore low expression lev-
els of miR-26a has been shown in Melanoma (34), lung 
cancer (35), breast cancer (36) and nasopharyngeal car-
cinoma (33). Most recently, Jinushi et al., identified that 
miR-26a expression level may be used as a prognostic 
biomarker in CRC (37).
This research will serve as a base for future studies. 
Taken together our finding indicated that the differ-
ential expression of circulating miRNAs may have po-
tential value in CRC diagnosis and might serve as novel 
minimally invasive molecular biomarker for this malig-
nancy. Although a limitation of this study was the rela-
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tively small number of patients and controls and fur-
ther large-scale experimental investigations are needed 
to verify the results of this study.
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